{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:52:05Z","timestamp":1791917525649,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40487-025-00413-8","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T10:22:15Z","timestamp":1768904535000},"page":"373-388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Characteristics, Treatment Patterns, and Outcomes of Patients with Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Analysis of Health Insurance Claims Data in Germany"],"prefix":"10.1007","volume":"14","author":[{"given":"Jennifer","family":"Stuart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evi","family":"Zhuleku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Mevius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Squires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chethan","family":"Ramamurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barthold","family":"Deiters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4572-0987","authenticated-orcid":false,"given":"Mehmet","family":"Burcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"413_CR1","doi-asserted-by":"publisher","first-page":"04109","DOI":"10.7189\/jogh.13.04109","volume":"13","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Rumgay H, Li M, Yu H, Pan H, Ni J. The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040. J Glob Health. 2023;13:04109.","journal-title":"J Glob Health"},{"key":"413_CR2","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1038\/modpathol.2009.1","volume":"22","author":"L Cheng","year":"2009","unstructured":"Cheng L, Montironi R, Davidson DD, Lopez-Beltran A. Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol. 2009;22:S70\u201395.","journal-title":"Mod Pathol"},{"issue":"3","key":"413_CR3","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/cas.14782","volume":"112","author":"K Shigeta","year":"2021","unstructured":"Shigeta K, Matsumoto K, Ogihara K, et al. The clinicopathological characteristics of muscle-invasive bladder recurrence in upper tract urothelial carcinoma. Cancer Sci. 2021;112(3):1084\u201394.","journal-title":"Cancer Sci"},{"key":"413_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/bs.acc.2021.07.005","volume":"107","author":"F Wilson","year":"2022","unstructured":"Wilson F, Joseph N, Choudhury A. Biomarkers in muscle invasive bladder cancer. Adv Clin Chem. 2022;107:265\u201397.","journal-title":"Adv Clin Chem"},{"issue":"3","key":"413_CR5","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"JP Stein","year":"2001","unstructured":"Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666\u201375.","journal-title":"J Clin Oncol"},{"issue":"9","key":"413_CR6","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859\u201366.","journal-title":"N Engl J Med"},{"issue":"1","key":"413_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.urology.2006.10.041","volume":"69","author":"CN Sternberg","year":"2007","unstructured":"Sternberg CN, Donat SM, Bellmunt J, et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology. 2007;69(1):62\u201379.","journal-title":"Urology"},{"key":"413_CR8","unstructured":"AWMF. S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorgedes Harnblasenkarzinoms, Langversion 2.0. 2020. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/032-038OL. Accessed 13 Sept 2025."},{"key":"413_CR9","unstructured":"EAU. Muscle-invasive and metastatic bladder cancer. 2024. https:\/\/uroweb.org\/guidelines\/muscle-invasive-and-metastatic-bladder-cancer\/chapter\/disease-management. Accessed 13 Sept 2025."},{"issue":"3","key":"413_CR10","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles T, Bellmunt J, Comperat E, et al. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(3):244\u201358.","journal-title":"Ann Oncol"},{"issue":"11","key":"413_CR11","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1007\/s00432-021-03582-x","volume":"147","author":"Y Lee","year":"2021","unstructured":"Lee Y, Kim YS, Hong B, Cho YM, Lee JL. Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC. J Cancer Res Clin Oncol. 2021;147(11):3421\u20139.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"18","key":"413_CR12","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.21.02051","volume":"40","author":"C Pfister","year":"2022","unstructured":"Pfister C, Gravis G, Fl\u00e9chon A, et al. Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial. J Clin Oncol. 2022;40(18):2013\u201322.","journal-title":"J Clin Oncol"},{"key":"413_CR13","unstructured":"AWMF. Subgruppeneffekte der Wirksamkeit und Sicherheit von organerhaltenden, adjuvanten und neoadjuvanten Therapien des muskelinvasiven Urothelkarzinoms der Harnblase \u2013 systematische \u00dcbersichtsarbeit und Subgruppenanalyse. 2020. https:\/\/register.awmf.org\/assets\/guidelines\/032-038OLeb_S3_Harnblasenkarzinom_2020-04.pdf. Accessed 13 Sept 2025."},{"issue":"3","key":"413_CR14","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/cncr.22031","volume":"107","author":"A Dash","year":"2006","unstructured":"Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006;107(3):506\u201313.","journal-title":"Cancer"},{"issue":"3","key":"413_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","volume":"12","author":"MD Galsky","year":"2011","unstructured":"Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011;12(3):211\u20134.","journal-title":"Lancet Oncol"},{"issue":"22","key":"413_CR16","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;384(22):2102\u201314.","journal-title":"N Engl J Med"},{"key":"413_CR17","unstructured":"IQWiG. Nivolumab: extract of Dossier Assessment. 2022. https:\/\/www.iqwig.de\/download\/a22-53_nivolumab_extract-of-dossier-assessment_v1-0.pdf. Accessed 13 Sept 2025."},{"key":"413_CR18","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles T, Catto JWF, Galsky MD, et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N Engl J Med. 2024;391:1773\u201386.","journal-title":"N Engl J Med"},{"issue":"4","key":"413_CR19","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s00345-023-04335-w","volume":"41","author":"M Roupret","year":"2023","unstructured":"Roupret M, Brouquet A, Colrat F, et al. Population characteristics, management, and survival outcomes in muscle-invasive urothelial carcinoma undergoing radical resection: the MINOTAUR study. World J Urol. 2023;41(4):1069\u201375.","journal-title":"World J Urol"},{"key":"413_CR20","volume-title":"Stata statistical software: release 18","author":"StataCorp","year":"2025","unstructured":"StataCorp. Stata statistical software: release 18. College Station: StataCorp; 2025."},{"issue":"7","key":"413_CR21","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s00345-022-04017-z","volume":"40","author":"L Flegar","year":"2022","unstructured":"Flegar L, Kraywinkel K, Zacharis A, et al. Treatment trends for muscle-invasive bladder cancer in Germany from 2006 to 2019. World J Urol. 2022;40(7):1715\u201321.","journal-title":"World J Urol"},{"key":"413_CR22","doi-asserted-by":"publisher","first-page":"S1342","DOI":"10.1016\/j.annonc.2022.07.1836","volume":"33","author":"A Fraslin","year":"2022","unstructured":"Fraslin A, Colrat FP, Karimi M, et al. 1758P Characteristics, management and survival outcomes of French patients (pts) with muscle invasive bladder cancer (MIBC) at high risk of recurrence (MIBC-HR): a study based on the COBLAnCE cohort. Ann Oncol. 2022;33:S1342.","journal-title":"Ann Oncol"},{"issue":"2","key":"413_CR23","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/jjco\/hyad152","volume":"54","author":"T Matsue","year":"2024","unstructured":"Matsue T, Kato M, Kosugi Y, et al. Investigation of eligibility for adjuvant therapy from real-world data of patients with urothelial carcinoma undergoing radical cystectomy and radical nephroureterectomy. Jpn J Clin Oncol. 2024;54(2):182\u201391.","journal-title":"Jpn J Clin Oncol"},{"key":"413_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2340\/1651-226X.2025.42052","volume":"64","author":"HS Haugnes","year":"2025","unstructured":"Haugnes HS, Kjaeve H, Bjerkaas E, Hellesnes R, Hjelle L, Larsen M. Real-world data on utilization of neoadjuvant chemotherapy for muscle invasive bladder cancer: impact on surgical complications and oncological efficacy. Acta Oncol. 2025;64:13\u201321.","journal-title":"Acta Oncol"},{"key":"413_CR25","doi-asserted-by":"publisher","first-page":"S1492","DOI":"10.1016\/j.annonc.2022.10.186","volume":"33","author":"A Hiong","year":"2022","unstructured":"Hiong A, Dundee P, Lawrentschuk N, et al. 151P Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer: real-world analysis of chemotherapy use and impact on patient outcomes. Ann Oncol. 2022;33:S1492.","journal-title":"Ann Oncol"},{"issue":"1","key":"413_CR26","first-page":"76.e15","volume":"39","author":"A Drakaki","year":"2021","unstructured":"Drakaki A, Pantuck A, Mhatre SK, et al. \u201cReal-world\u201d outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelialcarcinoma. Urol Oncol Semin Orig Investig. 2021;39(1):76.e15-76.e22.","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"4","key":"413_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70644","volume":"14","author":"BB Davies-Teye","year":"2025","unstructured":"Davies-Teye BB, Siddiqui MM, Zhang X, et al. Treatment patterns and radical cystectomy outcomes in patients diagnosed with urothelial nonmetastatic muscle-invasive bladder cancer in the United States. Cancer Med. 2025;14(4):e70644.","journal-title":"Cancer Med"},{"issue":"2","key":"413_CR28","first-page":"24","volume":"13","author":"JJ Duplisea","year":"2019","unstructured":"Duplisea JJ, Mason RJ, Reichard CA, et al. Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma. Can Urol Assoc J. 2019;13(2):24\u20138.","journal-title":"Can Urol Assoc J"},{"issue":"6","key":"413_CR29","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.urology.2013.07.055","volume":"82","author":"S Rehman","year":"2013","unstructured":"Rehman S, Crane A, Din R, et al. Understanding avoidance, refusal, and abandonment of chemotherapy before and after cystectomy for bladder cancer. Urology. 2013;82(6):1370\u20135.","journal-title":"Urology"},{"issue":"2","key":"413_CR30","first-page":"29","volume":"13","author":"MJ Raphael","year":"2019","unstructured":"Raphael MJ, Booth CM. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: underused across the 49(th) parallel. Can Urol Assoc J. 2019;13(2):29\u201331.","journal-title":"Can Urol Assoc J"},{"key":"413_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9092736","author":"U Anceschi","year":"2020","unstructured":"Anceschi U, Brassetti A, Tuderti G, et al. Impact of clinical response to neoadjuvant chemotherapy in the era of robot assisted radical cystectomy: results of a single-center experience. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9092736.","journal-title":"J Clin Med"},{"key":"413_CR32","doi-asserted-by":"crossref","unstructured":"International Collaboration of Trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet. 1999;354(9178):533\u201340.","DOI":"10.1016\/S0140-6736(99)02292-8"},{"issue":"1","key":"413_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.eururo.2021.09.028","volume":"81","author":"Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer","year":"2022","unstructured":"Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. A systematic review and meta-analysis of individual participant data from randomised controlled trials. Eur Urol. 2022;81(1):50\u201361.","journal-title":"Eur Urol"},{"issue":"13","key":"413_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.fjurol.2024.102744","volume":"34","author":"A Guilbert","year":"2024","unstructured":"Guilbert A, Lebret T, Oudard S, et al. Real-world evaluation of nivolumab utilization in adjuvant treatment of localized muscle-invasive urothelial carcinoma. French J Urol. 2024;34(13):102744.","journal-title":"French J Urol"},{"key":"413_CR35","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1200\/JCO.2025.43.5_suppl.704","volume":"43","author":"P Squires","year":"2025","unstructured":"Squires P, Meng K, Hu X, et al. Peri-operative treatment patterns in real-world muscle-invasive bladder cancer patients undergoing radical cystectomy in the era of adjuvant immunotherapy. J Clin Oncol. 2025;43:704\u201339.","journal-title":"J Clin Oncol"},{"key":"413_CR36","doi-asserted-by":"crossref","unstructured":"Squires P, Coutinho F, Tepsick J, et al. Real-world adjuvant nivolumab utilization in surgically treated muscle invasive bladder cancer patients within U.S. community oncology practice (poster presentation). Professional Society for Health Economics and Outcomes Research (ISPOR), Montreal, Canada: Value in Health. 2025.","DOI":"10.1016\/j.jval.2025.04.960"},{"issue":"6","key":"413_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2024.101811","volume":"15","author":"VC Rutten","year":"2024","unstructured":"Rutten VC, Al CM, Festen S, Zuiverloon TCM, Boormans JL, Polinder-Bos HA. Selecting the right treatment: health outcome priorities in older patients with bladder cancer. J Geriatr Oncol. 2024;15(6):101811.","journal-title":"J Geriatr Oncol"},{"issue":"12","key":"413_CR38","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1002\/cncr.32048","volume":"125","author":"AT Chu","year":"2019","unstructured":"Chu AT, Holt SK, Wright JL, et al. Delays in radical cystectomy for muscle-invasive bladder cancer. Cancer. 2019;125(12):2011\u20137.","journal-title":"Cancer"},{"issue":"5_suppl","key":"413_CR39","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1200\/JCO.2025.43.5_suppl.698","volume":"43","author":"JL Gore","year":"2025","unstructured":"Gore JL, Shih V, Kelkar S, et al. Clinical characteristics and treatment patterns of patients with muscle invasive bladder cancer: a real-world cohort study. J Clin Oncol. 2025;43(5_suppl):698.","journal-title":"J Clin Oncol"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00413-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-025-00413-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00413-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:44:28Z","timestamp":1773668668000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-025-00413-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["413"],"URL":"https:\/\/doi.org\/10.1007\/s40487-025-00413-8","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"13 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jennifer Stuart, Patrick Squires, Mehmet Burcu, and Chethan Ramamurthy are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Evi Zhuleku is an employee of Cytel Inc, whose work in this study was supported by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Antje Mevius is an employee of IPAM e.V. and declares no competing interests. Barthold Deiters is an employee of GWQ ServicePlus AG and declares no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The use of claims data provided by AOK PLUS and GWQ was permitted under the legal basis of \u00a775, Tenth Book of the Social Code (SGB X). As data was anonymized, ethical approval from an institutional review board and informed consent were not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}